An observational study in Biliary Atresia and Prognosis, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Children's Hospital of Fudan University · Observational
To investigate the role of preoperative serum FGF19 level in the prognosis of biliary atresia.
Kasai portoenterostomy is currently one of the main treatment methods for biliary atresia, but about 30% of children still require liver transplantation even after receiving the surgery. Accurate prognosis will help select the most suitable treatment method for children, but there is currently a lack of effective preoperative predictive indicators. Serum FGF19 has recently been considered a possible preoperative predictive indicator for biliary atresia, but its predictive value has not been confirmed in a large sample and in Asian population, thus the investigators try to further explore the prognostic value of serum FGF19 in children with biliary atresia based on a large sample.
75 studies on the registry are indexed under Biliary Atresia; 25 are open to participants now.
This study's planned enrollment of 200 is above the median of 126 across 31 observational studies indexed under Biliary Atresia.
Browse Biliary Atresia studies →Children's Hospital of Fudan University is the lead sponsor of 262 studies on the registry; 92 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study enrolled patients meeting following conditions.
Exclusion Criteria:
Good prognosis: the serum total bilirubin level was less than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery. Poor prognosis: the serum total bilirubin level was higher than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery.
Serum total bilirubin level (umol/l)
The difference of serum total bilirubin level will be measured with ELISA( Enzyme Linked ImmunoSorbent Assay) three months after surgery
Time frame: Three months after surgery
Native liver survival (%)
The difference of native liver survival will be measured according to the follow-up statue one year after surgery
Time frame: One year after surgery
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital of Fudan University